Commercialized multigene predictors of clinical outcome for breast cancer.
about
Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancerMicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancerBreast cancer in the personal genomics eraGene expression analysis in RA: towards personalized medicineAdvances in the Molecular Analysis of Breast Cancer: Pathway Toward Personalized MedicineThe cure: design and evaluation of a crowdsourcing game for gene selection for breast cancer survival predictionSelective genomic copy number imbalances and probability of recurrence in early-stage breast cancerPredictive and prognostic molecular markers for cancer medicineUtilizing the molecular gateway: the path to personalized cancer management.A pathway-based classification of breast cancer integrating data on differentially expressed genes, copy number variations and microRNA target genesOxidative status interactome map: towards novel approaches in experiment planning, data analysis, diagnostics and therapy.Study of integrated heterogeneous data reveals prognostic power of gene expression for breast cancer survival.Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancerIdentification and validation of housekeeping genes in brains of the desert locust Schistocerca gregaria under different developmental conditions.Survival Online: a web-based service for the analysis of correlations between gene expression and clinical and follow-up data.Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithmsA panel of neuron-enriched proteins as markers for traumatic brain injury in humans.Dysregulated miR-183 inhibits migration in breast cancer cells.Evaluation of external RNA controls for the standardisation of gene expression biomarker measurements.Effect of training-sample size and classification difficulty on the accuracy of genomic predictorsMMP-9 expression varies according to molecular subtypes of breast cancer.Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.The evolving role of mass spectrometry in cancer biomarker discoveryIs Chemoendocrine Treatment without Alternative?A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.Genome-based risk prediction for early stage breast cancer.Histological, molecular and functional subtypes of breast cancersUnbiased approaches to biomarker discovery in neurodegenerative diseasesBenefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic modelsA multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.Innovations in chemotherapy and radiation therapy: Implications and opportunities for the Asia-Pacific Rim.Prediction of individual response to anticancer therapy: historical and future perspectivesGene signatures of breast cancer progression and metastasis.Biologic markers determine both the risk and the timing of recurrence in breast cancer.Review of the clinical studies using the 21-gene assay.The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.gef gene expression in MCF-7 breast cancer cells is associated with a better prognosis and induction of apoptosis by p53-mediated signaling pathwayEffects of tissue handling on RNA integrity and microarray measurements from resected breast cancers.
P2860
Q21089802-6A86F356-DBFB-4D9A-BF6A-24A698A6BE79Q21195215-FD68CEB9-4E49-46AB-81BD-811B2BE1E445Q24602679-04F87F41-FEDE-4EBC-B99E-958E45113F20Q26825706-9070B2A3-C7A6-46F0-8CE8-B6104D19F17DQ27001994-2D296ACB-27D5-4AC4-B7DA-14EB0DC1FC29Q28651478-471E42DE-C38B-4BB1-B7AD-4EFFFCE4DC63Q28741460-32CEFB7A-1069-457F-B98C-E8EE6C9BA06DQ28743108-291C2F37-A8BC-4D15-A476-F6461E3B4F15Q30371443-8562D081-71E1-460D-AAC3-CC86734B4002Q30566202-6A115C83-335B-4A28-A5F2-0F6F1FF57F3DQ30630953-BD581ED3-7D61-412D-8163-39428E10760FQ30901352-E94B41B0-51D3-4716-A63D-1AD3F23AB289Q30938412-B3BAC74C-C039-4DBB-B716-016E8B0D0706Q33464716-FAAE164A-FA43-4A05-A7D2-D3681FE19F96Q33510463-254E4B3B-A3CF-477C-BC0A-EC4A162F5BFCQ33517983-821C141E-FC11-4B73-9672-5C07673BF4D1Q33651520-3AA93855-6342-4D96-8E3B-005662141C59Q33657708-E2C7180E-F403-4F8B-8FD1-DC549FE9FEF0Q33698660-2A267824-5CC3-428D-A290-586E8BB52415Q33755464-BB1E521A-AD59-4B11-9C9D-3C0098B155C5Q33892880-CC5E49B0-F9E0-45AC-8399-E835E96FC625Q34116451-B9AA18F6-6D2C-49DF-8C9C-24DE680FCAFDQ34128373-2A796F1F-28F2-4245-9CDE-80C53A3A7A75Q34171119-D3F4ACEB-41AD-45FB-88E4-BA5D8CA3B81FQ34215422-C2FEF741-98B9-482C-A5FD-E3962CBC8CBFQ34284263-B36DD5D5-324C-437C-8B90-1A9A3D70997FQ34325583-A4C306A1-4B12-4008-8609-1F79B42E6859Q34359289-94C4E48A-DCCB-48FD-A1DC-308ACC35149BQ34616569-47318957-2E1E-4633-A24B-70893720ADBBQ34625918-42135EE1-8060-47EE-8905-5B39F6F38C8EQ34988987-0EC42E18-C3E5-4450-BC4F-9E272F9AA946Q34989150-3C25E135-6738-4E05-8271-59CAE43E7ECBQ34991655-BFCDFD8A-F4B1-47DB-ABD3-02CF9FCEBBFCQ35024682-D5045333-3386-4327-91A8-AE63CD23BFE1Q35029477-5AF66DC7-18A6-45ED-8FEB-34AB9104A2FBQ35073921-41F76B39-2FD9-4DAA-AD1F-6528710EE853Q35584053-DAC165FE-5306-4F61-AF02-13B6CDB5B141Q35599773-B7AF89D6-CEF2-4D0A-9529-869F2F3B2291Q35600102-E2F67101-493E-4430-B958-BB4C01C04674Q35626576-FA7945EE-CB8F-4364-A35F-A4083E2A386B
P2860
Commercialized multigene predictors of clinical outcome for breast cancer.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Commercialized multigene predictors of clinical outcome for breast cancer.
@ast
Commercialized multigene predictors of clinical outcome for breast cancer.
@en
Commercialized multigene predictors of clinical outcome for breast cancer.
@nl
type
label
Commercialized multigene predictors of clinical outcome for breast cancer.
@ast
Commercialized multigene predictors of clinical outcome for breast cancer.
@en
Commercialized multigene predictors of clinical outcome for breast cancer.
@nl
prefLabel
Commercialized multigene predictors of clinical outcome for breast cancer.
@ast
Commercialized multigene predictors of clinical outcome for breast cancer.
@en
Commercialized multigene predictors of clinical outcome for breast cancer.
@nl
P2093
P1433
P1476
Commercialized multigene predictors of clinical outcome for breast cancer
@en
P2093
Gabriel N Hortobágyi
Jeffrey S Ross
Lajos Pusztai
W Fraser Symmans
P304
P356
10.1634/THEONCOLOGIST.2007-0248
P577
2008-05-01T00:00:00Z